News | May 07, 2023
Alembic Pharmaceuticals posts Q4FY2023 consolidated PAT at Rs. 152.60 Cr
The company has reported total income of Rs. 1407.34 crores during the period ended March 31, 2023
The company has reported total income of Rs. 1407.34 crores during the period ended March 31, 2023
The company has reported total income of Rs. 918.67 crores during the period ended March 31, 2023
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
The company has reported total income of Rs. 691.9 crores during the quarter ended December 31, 2022
The company has reported total income of Rs. 701 crores during the period ended December 31, 2022
The company has announced net revenue of Rs. 639.8 crore for Q3 FY23 as compared to Rs. 562.08 crore in the corresponding period of the previous year
The company completed paracetamol capacity expansion by 1,800 MTPA and the company is now focusing on frugal manufacturing practices to reduce raw material cost and expand margins
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
Subscribe To Our Newsletter & Stay Updated
